• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.25 -0.10 (-0.19%)
Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
October 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
October 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
October 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
September 30, 2026
From Genentech
Via Business Wire
News headline image
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
September 28, 2026
From Genentech
Via Business Wire
News headline image
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
September 23, 2026
From Genentech
Via Business Wire
News headline image
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
September 22, 2026
From Genentech
Via Business Wire
News headline image
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
September 17, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
September 17, 2026
From Genentech
Via Business Wire
News headline image
U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
September 10, 2026
From Genentech
Via Business Wire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
August 20, 2026
From Genentech
Via Business Wire
News headline image
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
August 18, 2026
From Genentech
Via Business Wire
News headline image
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy
July 15, 2026
From Genentech
Via Business Wire
News headline image
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
July 07, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
July 02, 2026
From Genentech
Via Business Wire
News headline image
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
June 30, 2026
From Genentech
Via Business Wire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
June 22, 2026
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
From BioMedWire
Via GlobeNewswire
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
June 18, 2026
From Genentech
Via Business Wire
News headline image
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
June 11, 2026
From Genentech
Via Business Wire
News headline image
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
June 02, 2026
From Genentech
Via Business Wire
News headline image
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
June 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
May 19, 2026
From Genentech
Via Business Wire
News headline image
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
April 30, 2026
From Genentech
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap